Q3 2025 Overview of Diabetes Glucagon Campaigns and Portfolio Expansion 

The diabetes glucagon market activity in Q3 2025 featured product approvals and initiatives focused on expanding access, enhancing education, and supporting both patients and healthcare professionals.

Baqsimi promoted its needle-free glucagon in a back-to-school digital campaign, emphasizing ease of use, temperature stability, and suitability for patients aged one and up.

Gvoke HypoPen used digital and print promotions to highlight its simple two-step use, quick action, and reliability, with caregiver training, patient stories, and back-to-school messaging on diabetes preparedness.

Lupin received FDA approval for its Glucagon for Injection USP, expanding its U.S. injectable portfolio and reinforcing its commitment to diabetes care access and innovation.

Zegalogue implemented a global restructuring to boost efficiency and diabetes growth, while promoting novoMEDLINK’s clinical tools, education, and pen training for HCPs.